Microbial amyloids in neurodegenerative amyloid diseases.
amyloid
microbiome
neurodegeneration
prion
Journal
The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646
Informations de publication
Date de publication:
02 Dec 2023
02 Dec 2023
Historique:
revised:
13
11
2023
received:
05
09
2023
accepted:
30
11
2023
pubmed:
2
12
2023
medline:
2
12
2023
entrez:
2
12
2023
Statut:
aheadofprint
Résumé
Human-disease associated amyloidogenic proteins are not unique in their ability to form amyloid fibrillar structures. Numerous microbes produce amyloidogenic proteins that have distinct functions for their physiology in their amyloid form, rather than solely detrimental. Emerging data indicate associations between various microbial organisms, including those which produce functional amyloids, with neurodegenerative diseases. Here, we review some of the evidence suggesting that microbial amyloids impact amyloid disease in host organisms. Experimental data are building a foundation for continued lines of enquiry and suggest that that direct or indirect interactions between microbial and host amyloids may be a contributor to amyloid pathologies. Inhibiting microbial amyloids or their interactions with the host may therefore represent a tangible target to limit various amyloid pathologies.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIEHS NIH HHS
ID : 1R01ES032440
Pays : United States
Informations de copyright
© 2023 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Jucker M & Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51.
Jucker M & Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21, 1341-1349.
Yadollahikhales G & Rojas JC (2023) Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update. Neurotherapeutics 20, 914-931.
Balistreri A, Goetzler E & Chapman M (2020) Functional amyloids are the rule rather than the exception in cellular biology. Microorganisms 8, 1951.
Levkovich SA, Gazit E & Laor Bar-Yosef D (2021) Two decades of studying functional amyloids in microorganisms. Trends Microbiol 29, 251-265.
Eisenberg DS & Sawaya MR (2017) Structural studies of amyloid proteins at the molecular level. Annu Rev Biochem 86, 69-95.
Ke PC, Zhou R, Serpell LC, Riek R, Knowles TPJ, Lashuel HA, Gazit E, Hamley IW, Davis TP, Fändrich M et al. (2020) Half a century of amyloids: past, present and future. Chem Soc Rev 49, 5473-5509.
Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R & Eisenberg D (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773-778.
Sunde M & Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50, 123-159.
Lee M, Yau WM, Louis JM & Tycko R (2023) Structures of brain-derived 42-residue amyloid-beta fibril polymorphs with unusual molecular conformations and intermolecular interactions. Proc Natl Acad Sci USA 120, e2218831120.
Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney JM, Kim JK, Barclay AM, Kendall A et al. (2016) Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nat Struct Mol Biol 23, 409-415.
Liberta F, Loerch S, Rennegarbe M, Schierhorn A, Westermark P, Westermark GT, Hazenberg BPC, Grigorieff N, Fändrich M & Schmidt M (2019) Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. Nat Commun 10, 1104.
Gallardo R, Iadanza MG, Xu Y, Heath GR, Foster R, Radford SE & Ranson NA (2020) Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly. Nat Struct Mol Biol 27, 1048-1056.
Tomasello G, Armenia I & Molla G (2020) The protein imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities. Bioinformatics 36, 2909-2911.
Lin M, Mackie PM, Shaerzadeh F, Gamble-George J, Miller DR, Martyniuk CJ & Khoshbouei H (2021) In Parkinson's patient-derived dopamine neurons, the triplication of alpha-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition. Acta Neuropathol Commun 9, 107.
Bendor JT, Logan TP & Edwards RH (2013) The function of alpha-synuclein. Neuron 79, 1044-1066.
Fanutza T, del Prete D, Ford MJ, Castillo PE & D'Adamio L (2015) APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. Elife 4, e09743.
Dunot J, Ribera A, Pousinha PA & Marie H (2023) Spatiotemporal insights of APP function. Curr Opin Neurobiol 82, 102754.
Beatman EL, Massey A, Shives KD, Burrack KS, Chamanian M, Morrison TE & Beckham JD (2015) Alpha-Synuclein expression restricts RNA viral infections in the brain. J Virol 90, 2767-2782.
Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED et al. (2017) Holocranohistochemistry enables the visualization of alpha-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. J Neural Transm (Vienna) 124, 721-738.
Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE et al. (2016) Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci Transl Med 8, 340ra72.
Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE et al. (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE 5, e9505.
Bronstein JM, Zeiger WA & Peng C (2023) Abandoning the Proteinopathy paradigm in Parkinson disease-not so fast. JAMA Neurol 80, 872-873.
Espay AJ & Okun MS (2023) Abandoning the Proteinopathy paradigm in Parkinson disease. JAMA Neurol 80, 123-124.
Berdynski M, Miszta P, Safranow K, Andersen PM, Morita M, Filipek S, Żekanowski C & Kuźma-Kozakiewicz M (2022) SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci Rep 12, 103.
Klein S, Goldman A, Lee H, Ghahremani S, Bhakta V, UCLA Clinical Genomics Center, Nelson SF & Martinez-Agosto JA (2016) Truncating mutations in APP cause a distinct neurological phenotype. Ann Neurol 80, 456-460.
Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL et al. (2010) Alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA 107, 19573-19578.
Wells C, Brennan S, Keon M & Ooi L (2021) The role of amyloid oligomers in neurodegenerative pathologies. Int J Biol Macromol 181, 582-604.
Li D & Liu C (2022) Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nat Rev Neurosci 23, 523-534.
Zhang S, Dauer K, Strohäker T, Tatenhorst L, Caldi Gomes L, Mayer S, Jung BC, Kim WS, Lee SJ, Becker S et al. (2023) Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain. Brain Pathol 33, e13196.
Sokratian A, Ziaee J, Kelly K, Chang A, Bryant N, Wang S, Xu E, Li JY, Wang SH, Ervin J et al. (2021) Heterogeneity in alpha-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. Acta Neuropathol 141, 547-564.
Suzuki G, Imura S, Hosokawa M, Katsumata R, Nonaka T, Hisanaga SI, Saeki Y & Hasegawa M (2020) Alpha-synuclein strains that cause distinct pathologies differentially inhibit proteasome. Elife 9, e56825.
Choi ML, Chappard A, Singh BP, Maclachlan C, Rodrigues M, Fedotova EI, Berezhnov AV, De S, Peddie CJ, Athauda D et al. (2022) Pathological structural conversion of alpha-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25, 1134-1148.
de la Cueva M, Antequera D, Ordoñez-Gutierrez L, Wandosell F, Camins A, Carro E & Bartolome F (2022) Amyloid-beta impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models. Sci Rep 12, 10092.
Devi L, Raghavendran V, Prabhu BM, Avadhani NG & Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283, 9089-9100.
Ludtmann MH, Angelova PR, Ninkina NN, Gandhi S, Buchman VL & Abramov AY (2016) Monomeric alpha-Synuclein exerts a physiological role on brain ATP synthase. J Neurosci 36, 10510-10521.
Tafuri F, Ronchi D, Magri F, Comi GP & Corti S (2015) SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front Cell Neurosci 9, 336.
Tan W, Pasinelli P & Trotti D (2014) Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim Biophys Acta 1842, 1295-1301.
Thorne NJ & Tumbarello DA (2022) The relationship of alpha-synuclein to mitochondrial dynamics and quality control. Front Mol Neurosci 15, 947191.
Gonzalez-Rodriguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, Tkatch T, Stavarache MA, Wokosin DL, Gao L et al. (2021) Disruption of mitochondrial complex I induces progressive parkinsonism. Nature 599, 650-656.
Surmeier DJ, Obeso JA & Halliday GM (2017) Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 18, 101-113.
Sarkar S, Olsen AL, Sygnecka K, Lohr KM & Feany MB (2021) Alpha-synuclein impairs autophagosome maturation through abnormal Actin stabilization. PLoS Genet 17, e1009359.
Gregori L, Fuchs C, Figueiredo-Pereira ME, van Nostrand WE & Goldgaber D (1995) Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 270, 19702-19708.
Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ & Layfield R (2000) Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 97, 9902-9906.
Tseng BP, Green KN, Chan JL, Blurton-Jones M & LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29, 1607-1618.
Harms AS, Kordower JH, Sette A, Lindestam Arlehamn CS, Sulzer D & Mach RH (2021) Inflammation in experimental models of alpha-Synucleinopathies. Mov Disord 36, 37-49.
Dallas ML & Widera D (2021) TLR2 and TLR4-mediated inflammation in Alzheimer's disease: self-defense or sabotage? Neural Regen Res 16, 1552-1553.
Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ et al. (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4, 1562.
Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M, Stafa K, Lee HJ, Lee SJ & Masliah E (2015) Antagonizing neuronal toll-like receptor 2 prevents Synucleinopathy by activating autophagy. Cell Rep 13, 771-782.
Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ et al. (2018) Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol Neurodegener 13, 43.
Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rübe CE, Walter J, Heneka MT, Hartmann T et al. (2012) TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation. J Immunol 188, 1098-1107.
Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, Voigt RM, Naqib A, Green SJ, Kordower JH et al. (2019) Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut 68, 829-843.
Dutta D, Jana M, Paidi RK, Majumder M, Raha S, Dasarathy S & Pahan K (2023) Tau fibrils induce glial inflammation and neuropathology via TLR2 in Alzheimer's disease-related mouse models. J Clin Invest 133, e161987.
Liu Y, Dai Y, Li Q, Chen C, Chen H, Song Y, Hua F & Zhang Z (2020) Beta-amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia. Neurosci Lett 736, 135279.
Meng JX, Zhang Y, Saman D, Haider AM, De S, Sang JC, Brown K, Jiang K, Humphrey J, Julian L et al. (2022) Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses. Nat Commun 13, 2692.
Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP & Appel SH (2010) Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58, 231-243.
Carroll JA, Race B, Williams K & Chesebro B (2018) Toll-like receptor 2 confers partial neuroprotection during prion disease. PLoS ONE 13, e0208559.
Westwell-Roper C, Denroche HC, Ehses JA & Verchere CB (2016) Differential activation of innate immune pathways by distinct islet amyloid polypeptide (IAPP) aggregates. J Biol Chem 291, 8908-8917, 17.
Moreira J, Martins H, Saraiva M & Saraiva MJ (2023) TLR2 and 4 signaling pathways are altered in macrophages from V30M TTR mice with down-regulated expression of chemokines. Clin Sci (Lond) 137, 355-366.
Abramov AY, Potapova EV, Dremin VV & Dunaev AV (2020) Interaction of oxidative stress and misfolded proteins in the mechanism of neurodegeneration. Life (Basel) 10, 101.
Igel A, Fornara B, Rezaei H & Béringue V (2023) Prion assemblies: structural heterogeneity, mechanisms of formation, and role in species barrier. Cell Tissue Res 392, 149-166.
Braak H, Rüb U, Gai WP & del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110, 517-536.
Del Tredici K & Braak H (2008) A not entirely benign procedure: progression of Parkinson's disease. Acta Neuropathol 115, 379-384.
Brettschneider J, Tredici KD, Lee VMY & Trojanowski JQ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16, 109-120.
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA et al. (2019) Transneuronal propagation of pathologic alpha-Synuclein from the gut to the brain models Parkinson's disease. Neuron 103, 627-641.e7.
Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, Tsung-Pin P, Riess O, Nyengaard JR, Tamgüney G et al. (2019) Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol 138, 535-550.
Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M & Jucker M (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330, 980-982.
Schoonhoven DN, Coomans EM, Millán AP, van Nifterick AM, Visser D, Ossenkoppele R, Tuncel H, van der Flier WM, Golla SSV, Scheltens P et al. (2023) Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study. Brain 146, 4040-4054.
Ruiz-Riquelme A, Lau HHC, Stuart E, Goczi AN, Wang Z, Schmitt-Ulms G & Watts JC (2018) Prion-like propagation of beta-amyloid aggregates in the absence of APP overexpression. Acta Neuropathol Commun 6, 26.
Ayers JI, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ & Giasson BI (2017) Robust central nervous system pathology in transgenic mice following peripheral injection of alpha-Synuclein fibrils. J Virol 91, e02095-16.
Davies GA, Bryant AR, Reynolds JD, Jirik FR & Sharkey KA (2006) Prion diseases and the gastrointestinal tract. Can J Gastroenterol 20, 18-24.
Dueholm MS, Albertsen M, Otzen D & Nielsen PH (2012) Curli functional amyloid systems are phylogenetically widespread and display large diversity in operon and protein structure. PLoS ONE 7, e51274.
Harrison PM (2019) Evolutionary behaviour of bacterial prion-like proteins. PLoS ONE 14, e0213030.
Perov S, Lidor O, Salinas N, Golan N, Tayeb- Fligelman E, Deshmukh M, Willbold D & Landau M (2019) Structural insights into Curli CsgA cross-beta fibril architecture inspire repurposing of anti-amyloid compounds as anti-biofilm agents. PLoS Pathog 15, e1007978.
Diehl A, Roske Y, Ball L, Chowdhury A, Hiller M, Molière N, Kramer R, Stöppler D, Worth CL, Schlegel B et al. (2018) Structural changes of TasA in biofilm formation of Bacillus subtilis. Proc Natl Acad Sci USA 115, 3237-3242.
Tayeb-Fligelman E, Tabachnikov O, Moshe A, Goldshmidt-Tran O, Sawaya MR, Coquelle N, Colletier JP & Landau M (2017) The cytotoxic Staphylococcus aureus PSMalpha3 reveals a cross-alpha amyloid-like fibril. Science 355, 831-833.
Larsen P, Nielsen JL, Dueholm MS, Wetzel R, Otzen D & Nielsen PH (2007) Amyloid adhesins are abundant in natural biofilms. Environ Microbiol 9, 3077-3090.
Larsen P, Nielsen JL, Otzen D & Nielsen PH (2008) Amyloid-like adhesins produced by floc-forming and filamentous bacteria in activated sludge. Appl Environ Microbiol 74, 1517-1526.
Gil-Garcia M, Iglesias V, Pallarès I & Ventura S (2021) Prion-like proteins: from computational approaches to proteome-wide analysis. FEBS Open Bio 11, 2400-2417.
Rasko DA, Rosovitz MJ, Myers GSA, Mongodin EF, Fricke WF, Gajer P, Crabtree J, Sebaihia M, Thomson NR, Chaudhuri R et al. (2008) The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol 190, 6881-6893.
Yang X, Tran F & Zhang P (2023) Comparative genomic analyses of Escherichia coli from a meat processing environment in relation to their biofilm formation and persistence. Microbiol Spectr 11, e0018323.
Nicastro LK, Tursi SA, Le LS, Miller AL, Efimov A, Buttaro B, Tam V & Tükel Ç (2019) Cytotoxic Curli intermediates form during salmonella biofilm development. J Bacteriol 201, e00095-19.
Evans ML & Chapman MR (2014) Curli biogenesis: order out of disorder. Biochim Biophys Acta 1843, 1551-1558, 1558.
Chorell E, Andersson E, Evans ML, Jain N, Götheson A, Åden J, Chapman MR, Almqvist F & Wittung-Stafshede P (2015) Bacterial chaperones CsgE and CsgC differentially modulate human alpha-Synuclein amyloid formation via transient contacts. PLoS ONE 10, e0140194.
Evans ML, Chorell E, Taylor JD, Åden J, Götheson A, Li F, Koch M, Sefer L, Matthews SJ, Wittung-Stafshede P et al. (2015) The bacterial curli system possesses a potent and selective inhibitor of amyloid formation. Mol Cell 57, 445-455.
Hufnagel DA, Tukel C & Chapman MR (2013) Disease to dirt: the biology of microbial amyloids. PLoS Pathog 9, e1003740.
Tursi SA & Tukel C (2018) Curli-containing enteric biofilms inside and out: matrix composition, immune recognition, and disease implications. Microbiol Mol Biol Rev 82, e00028-18.
Salinas N, Povolotsky TL, Landau M & Kolodkin-Gal I (2020) Emerging roles of functional bacterial amyloids in gene regulation, toxicity, and immunomodulation. Microbiol Mol Biol Rev 85, e00062-20.
Van Gerven N, Klein RD, Hultgren SJ & Remaut H (2015) Bacterial amyloid formation: structural insights into curli biogensis. Trends Microbiol 23, 693-706.
Elias S & Banin E (2012) Multi-species biofilms: living with friendly neighbors. FEMS Microbiol Rev 36, 990-1004.
Rendueles O & Ghigo JM (2012) Multi-species biofilms: how to avoid unfriendly neighbors. FEMS Microbiol Rev 36, 972-989.
Miller AL, Bessho S, Grando K & Tükel Ç (2021) Microbiome or infections: amyloid-containing biofilms as a trigger for complex human diseases. Front Immunol 12, 638867.
Vidakovic L, Singh PK, Hartmann R, Nadell CD & Drescher K (2018) Dynamic biofilm architecture confers individual and collective mechanisms of viral protection. Nat Microbiol 3, 26-31.
Biesecker SG, Nicastro LK, Wilson RP & Tükel Ç (2018) The functional amyloid Curli protects Escherichia coli against complement-mediated bactericidal activity. Biomolecules 8, 5.
Van Gerven N, Van der Verren SE, Reiter DM & Remaut H (2018) The role of functional amyloids in bacterial virulence. J Mol Biol 430, 3657-3684.
Kai-Larsen Y, Lüthje P, Chromek M, Peters V, Wang X, Holm Å, Kádas L, Hedlund KO, Johansson J, Chapman MR et al. (2010) Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 6, e1001010.
Wang R, Braughton KR, Kretschmer D, Bach THL, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A et al. (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13, 1510-1514.
Steinberg N, Keren-Paz A, Hou Q, Doron S, Yanuka-Golub K, Olender T, Hadar R, Rosenberg G, Jain R, Cámara-Almirón J et al. (2020) The extracellular matrix protein TasA is a developmental cue that maintains a motile subpopulation within Bacillus subtilis biofilms. Sci Signal 13, eaaw8905.
Pallares I, Iglesias V & Ventura S (2015) The rho termination factor of Clostridium botulinum contains a prion-like domain with a highly Amyloidogenic Core. Front Microbiol 6, 1516.
Malabirade A, Morgado-Brajones J, Trépout S, Wien F, Marquez I, Seguin J, Marco S, Velez M & Arluison V (2017) Membrane association of the bacterial riboregulator Hfq and functional perspectives. Sci Rep 7, 10724.
Zhou Y, Smith D, Leong BJ, Brännström K, Almqvist F & Chapman MR (2012) Promiscuous cross-seeding between bacterial amyloids promotes interspecies biofilms. J Biol Chem 287, 35092-35103.
Katorcha E, Makarava N, Lee YJ, Lindberg I, Monteiro MJ, Kovacs GG & Baskakov IV (2017) Cross-seeding of prions by aggregated alpha-synuclein leads to transmissible spongiform encephalopathy. PLoS Pathog 13, e1006563.
Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J & Soto C (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30, 4528-4535.
Morales R, Moreno-Gonzalez I & Soto C (2013) Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog 9, e1003537.
Ono K, Takahashi R, Ikeda T & Yamada M (2012) Cross-seeding effects of amyloid beta-protein and alpha-synuclein. J Neurochem 122, 883-890.
Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ & LaFerla FM (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30, 7281-7289.
Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ & Lee VMY (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640.
Spires-Jones TL, Attems J & Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134, 187-205.
Vasconcelos B, Stancu IC, Buist A, Bird M, Wang P, Vanoosthuyse A, van Kolen K, Verheyen A, Kienlen-Campard P, Octave JN et al. (2016) Heterotypic seeding of tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of tau-pathology in vivo. Acta Neuropathol 131, 549-569.
Rahimi J & Kovacs GG (2014) Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 6, 82.
Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ et al. (2013) Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103-117.
Guo JP, Arai T, Miklossy J & McGeer PL (2006) Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 103, 1953-1958.
Lundmark K, Westermark GT, Olsén A & Westermark P (2005) Protein fibrils in nature can enhance amyloid protein a amyloidosis in mice: cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 102, 6098-6102.
Hartman K, Brender JR, Monde K, Ono A, Evans ML, Popovych N, Chapman MR & Ramamoorthy A (2013) Bacterial curli protein promotes the conversion of PAP248-286 into the amyloid SEVI: cross-seeding of dissimilar amyloid sequences. PeerJ 1, e5.
Sampson TR, Challis C, Jain N, Moiseyenko A, Ladinsky MS, Shastri GG, Thron T, Needham BD, Horvath I, Debelius JW et al. (2020) A gut bacterial amyloid promotes alpha-synuclein aggregation and motor impairment in mice. Elife 9, e53111.
Christensen LFB, Jensen KF, Nielsen J, Vad BS, Christiansen G & Otzen DE (2019) Reducing the Amyloidogenicity of functional amyloid protein FapC increases its ability to inhibit alpha-Synuclein fibrillation. ACS Omega 4, 4029-4039.
Bhoite SS, Han Y, Ruotolo BT & Chapman MR (2022) Mechanistic insights into accelerated alpha-synuclein aggregation mediated by human microbiome-associated functional amyloids. J Biol Chem 298, 102088.
Jain N, Ådén J, Nagamatsu K, Evans ML, Li X, McMichael B, Ivanova MI, Almqvist F, Buxbaum JN & Chapman MR (2017) Inhibition of curli assembly and Escherichia coli biofilm formation by the human systemic amyloid precursor transthyretin. Proc Natl Acad Sci USA 114, 12184-12189.
Haikal C, Ortigosa-Pascual L, Najarzadeh Z, Bernfur K, Svanbergsson A, Otzen DE, Linse S & Li JY (2021) The bacterial amyloids phenol soluble Modulins from Staphylococcus aureus catalyze alpha-Synuclein aggregation. Int J Mol Sci 22, 11594.
Fung TC, Olson CA & Hsiao EY (2017) Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci 20, 145-155.
Sharon G, Sampson TR, Geschwind DH & Mazmanian SK (2016) The central nervous system and the gut microbiome. Cell 167, 915-932.
Fang P, Kazmi SA, Jameson KG & Hsiao EY (2020) The microbiome as a modifier of neurodegenerative disease risk. Cell Host Microbe 28, 201-222.
Chen SG, Stribinskis V, Rane MJ, Demuth DR, Gozal E, Roberts AM, Jagadapillai R, Liu R, Choe K, Shivakumar B et al. (2016) Exposure to the functional bacterial amyloid protein Curli enhances alpha-Synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci Rep 6, 34477.
Peelaerts W, Mercado G, George S, Villumsen M, Kasen A, Aguileta M, Linstow C, Sutter AB, Kuhn E, Stetzik L et al. (2023) Urinary tract infections trigger synucleinopathy via the innate immune response. Acta Neuropathol 145, 541-559.
Schreiber HLT, Conover MS, Chou W-C, Hibbing ME, Manson AL, Dodson KW, Hannan TJ, Roberts PL, Stapleton AE, Hooton TM et al. (2017) Bacterial virulence phenotypes of Escherichia coli and host susceptibility determine risk for urinary tract infections. Sci Transl Med 9, eaaf1283.
Wang C, Lau CY, Ma F & Zheng C (2021) Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration. Proc Natl Acad Sci USA 118, e2106504118.
Kurlawala Z, McMillan JD, Singhal RA, Morehouse J, Burke DA, Sears SM, Duregon E, Beverly LJ, Siskind LJ & Friedland RP (2023) Mutant and curli-producing E. coli enhance the disease phenotype in a hSOD1-G93A mouse model of ALS. Sci Rep 13, 5945.
Tukel C, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA & Bäumler AJ (2009) Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. Cell Host Microbe 6, 45-53.
Gallo PM, Rapsinski GJ, Wilson RP, Oppong GO, Sriram U, Goulian M, Buttaro B, Caricchio R, Gallucci S & Tükel Ç (2015) Amyloid-DNA composites of bacterial biofilms stimulate autoimmunity. Immunity 42, 1171-1184.
Garg P, Maass F, Sundaram SM, Mollenhauer B, Mahajani S, van Riesen C, Kügler S & Bähr M (2022) The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease. Mol Cell Neurosci 121, 103746.
Kronimus Y, Albus A, Balzer-Geldsetzer M, Straub S, Semler E, Otto M, Klotsche J, Dodel R, LANDSCAPE Consortium & Mengel D (2016) Naturally occurring autoantibodies against tau protein are reduced in Parkinson's disease dementia. PLoS ONE 11, e0164953.
Shalash A, Salama M, Makar M, Roushdy T, Elrassas HH, Mohamed W, el-Balkimy M & Abou Donia M (2017) Elevated serum alpha-Synuclein autoantibodies in patients with Parkinson's disease relative to Alzheimer's disease and controls. Front Neurol 8, 720.
van Blitterswijk M, Gulati S, Smoot E, Jaffa M, Maher N, Hyman BT, Ivinson AJ, Scherzer CR, Schoenfeld DA, Cudkowicz ME et al. (2011) Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12, 430-438.
Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J, Xu ZQ, Zhou HD, Doecke JD, Villemagne VL et al. (2021) Association of naturally occurring antibodies to beta-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. Sci Adv 7, eabb0457.
Scott KM, Kouli A, Yeoh SL, Clatworthy MR & Williams-Gray CH (2018) A systematic review and meta-analysis of alpha Synuclein auto-antibodies in Parkinson's disease. Front Neurol 9, 815.
Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, Phillips E, Mallal S, Roederer M, Marder KS et al. (2020) Alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nat Commun 11, 1875.
Lindestam Arlehamn CS, Pham J, Alcalay RN, Frazier A, Shorr E, Carpenter C, Sidney J, Dhanwani R, Agin-Liebes J, Garretti F et al. (2019) Widespread tau-specific CD4 T cell reactivity in the general population. J Immunol 203, 84-92.
Singhania A, Pham J, Dhanwani R, Frazier A, Rezende Dutra J, Marder KS, Phillips E, Mallal S, Amara AW, Standaert DG et al. (2021) The TCR repertoire of alpha-synuclein-specific T cells in Parkinson's disease is surprisingly diverse. Sci Rep 11, 302.
Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ & Weiner HL (2003) Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 112, 415-422.
Garretti F, Monahan C, Sloan N, Bergen J, Shahriar S, Kim SW, Sette A, Cutforth T, Kanter E, Agalliu D et al. (2023) Interaction of an alpha-synuclein epitope with HLA-DRB1(*)15:01 triggers enteric features in mice reminiscent of prodromal Parkinson's disease. Neuron 111, 3397-3413.e5.
Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG & Harms AS (2021) CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease. Brain 144, 2047-2059.
Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F et al. (2022) Neurodegeneration by alpha-synuclein-specific T cells in AAV-A53T-alpha-synuclein Parkinson's disease mice. Brain Behav Immun 101, 194-210.
Golan N, Engelberg Y & Landau M (2022) Structural mimicry in microbial and antimicrobial amyloids. Annu Rev Biochem 91, 403-422.
Garabatos N & Santamaria P (2022) Gut microbial antigenic mimicry in autoimmunity. Front Immunol 13, 873607.
Friedland RP (2015) Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis 45, 349-362.
Chandra R, Hiniker A, Kuo YM, Nussbaum RL & Liddle RA (2017) Alpha-Synuclein in gut endocrine cells and its implications for Parkinson's disease. JCI Insight 2, e92295.
Marshall A, Bradford BM, Clarke AR, Manson JC & Mabbott NA (2018) Oral prion Neuroinvasion occurs independently of PrP(C) expression in the gut epithelium. J Virol 92, e01010-18.
Cintron AF, Dalal NV, Dooyema J, Betarbet R & Walker LC (2015) Transport of cargo from periphery to brain by circulating monocytes. Brain Res 1622, 328-338.
Nagatake T, Fujita H, Minato N & Hamazaki Y (2014) Enteroendocrine cells are specifically marked by cell surface expression of claudin-4 in mouse small intestine. PLoS ONE 9, e90638.
Challis C, Hori A, Sampson TR, Yoo BB, Challis RC, Hamilton AM, Mazmanian SK, Volpicelli-Daley LA & Gradinaru V (2020) Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci 23, 327-336.
Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H & Takahashi R (2018) Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13, 21.
Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, Wang ZY, Roybon L, Melki R & Li JY (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128, 805-820.
Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P & Sørensen HT (2015) Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 78, 522-529.
Killinger BA, Madaj Z, Sikora JW, Rey N, Haas AJ, Vepa Y, Lindqvist D, Chen H, Thomas PM, Brundin P et al. (2018) The vermiform appendix impacts the risk of developing Parkinson's disease. Sci Transl Med 10, eaar5280.
Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M et al. (2015) Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30, 350-358.
Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR & Payami H (2022) Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun 13, 6958.
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C et al. (2017) Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 49, 60-68.
Haran JP, Bhattarai SK, Foley SE, Dutta P, Ward DV, Bucci V, McCormick BA, Gilbert J & Faith J (2019) Alzheimer's disease microbiome is associated with dysregulation of the anti-inflammatory P-glycoprotein pathway. MBio 10, e00632-19.
Friedland RP & Chapman MR (2017) The role of microbial amyloid in neurodegeneration. PLoS Pathog 13, e1006654.
Schmit KJ, Sciortino A, Aho VTE, Garcia P, Rodriguez BP, Thomas MH, Gérardy J-J, Halder R, Cialini C, Heurtaux T et al. (2022) Dietary fibre deprivation and bacterial curli exposure shift gut microbiome and exacerbate Parkinson's disease-like pathologies in an alpha-synuclein-overexpressing mouse. bioRxiv. doi: 10.1101/2022.03.21.485143
Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K & Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107, 7710-7715.
Serra DO, Mika F, Richter AM & Hengge R (2016) The green tea polyphenol EGCG inhibits E. coli biofilm formation by impairing amyloid curli fibre assembly and downregulating the biofilm regulator CsgD via the sigma(E)-dependent sRNA RybB. Mol Microbiol 101, 136-151.
Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK et al. (2015) Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585-1595.